A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)

Trial Profile

A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Cediranib (Primary)
  • Indications Alveolar soft part sarcoma
  • Focus Therapeutic Use
  • Acronyms CASPS
  • Most Recent Events

    • 17 Oct 2017 Planned End Date changed from 1 Jul 2019 to 29 Jul 2018.
    • 02 Jun 2017 Primary endpoint (Percentage change in the sum of target marker lesion diameters (TMLsum) from randomisation to week 24 (or progression if sooner) compared to treatment with placebo) has been met, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top